Claris Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History

Claris Advisors’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-500	Closed	-$7.69K	–	83
2024 Q3	$7.69K	Buy	+500	New	+$8.34K	﹤0.01%	242

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Claris Advisors's ACAD Position: Q4 2024 in Review

Claris Advisors sold out of Acadia Pharmaceuticals (ACAD) in Q4 2024, closing a stake of 500 shares — an estimated $7.69K sold.

Claris Advisors first reported a position in ACAD in Q3 2024 and held it in 1 quarter. The position peaked at $7.69K in Q3 2024. 296 funds tracked by Wall St. Rank hold ACAD as of Q4 2024.

Claris Advisors reported no remaining Acadia Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Claris Advisors sold 500 Acadia Pharmaceuticals shares in Q4 2024, an estimated $7.69K.
Claris Advisors first reported a position in Acadia Pharmaceuticals in Q3 2024 and held it in 1 quarter.
Claris Advisors's Acadia Pharmaceuticals position peaked at $7.69K in Q3 2024.
296 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2024.

Based on Claris Advisors's 13F filing for Q4 2024, filed 7 Feb 2025.